Hepatitis E future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Attending to the impact of hepatitis E worldwide, further studies are required to [[diagnose]] and treat severe cases of the disease. Patients with elevated liver transaminases, particularly immunocompromised and end-stage liver disease patients should be tested for the presence of HEV RNA. Infected pregnant women also have an increased risk of complications, and should be tested and treated as well. | Attending to the impact of hepatitis E worldwide, further studies are required to [[diagnose]] and treat severe cases of the disease. Patients with elevated liver transaminases, particularly immunocompromised and end-stage liver disease patients should be tested for the presence of HEV RNA. Infected pregnant women also have an increased risk of complications, and should be tested and treated as well.<ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046 }} </ref><ref name="pmid22537448">{{cite journal| author=Wedemeyer H, Pischke S, Manns MP| title=Pathogenesis and treatment of hepatitis e virus infection. | journal=Gastroenterology | year= 2012 | volume= 142 | issue= 6 | pages= 1388-1397.e1 | pmid=22537448 | doi=10.1053/j.gastro.2012.02.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22537448 }} </ref> | ||
Further studies are required to answer questions such as:<ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046 }} </ref><ref name="pmid22537448">{{cite journal| author=Wedemeyer H, Pischke S, Manns MP| title=Pathogenesis and treatment of hepatitis e virus infection. | journal=Gastroenterology | year= 2012 | volume= 142 | issue= 6 | pages= 1388-1397.e1 | pmid=22537448 | doi=10.1053/j.gastro.2012.02.014 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22537448 }} </ref> | |||
*What are the areas of hyperendemnicity? | |||
*Which [[serotype]]s prevail in different areas? | |||
*What is the real percentage of [[asymptomatic]] [[infection]]? | |||
*Other potential routes of [[infection]]? | |||
*What is the real risk of [[transmission]] of [[HEV]] through [[blood transfusion]]s? | |||
*What [[genotype]]s can cause chronic [[infection]]? | |||
*Mechanism of interaction between [[T-cell]]s and [[HEV]]? | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 19:33, 25 August 2014
|
Hepatitis E Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Hepatitis E future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Hepatitis E future or investigational therapies |
|
Risk calculators and risk factors for Hepatitis E future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Attending to the impact of hepatitis E worldwide, further studies are required to diagnose and treat severe cases of the disease. Patients with elevated liver transaminases, particularly immunocompromised and end-stage liver disease patients should be tested for the presence of HEV RNA. Infected pregnant women also have an increased risk of complications, and should be tested and treated as well.[1][2]
Further studies are required to answer questions such as:[1][2]
- What are the areas of hyperendemnicity?
- Which serotypes prevail in different areas?
- What is the real percentage of asymptomatic infection?
- Other potential routes of infection?
- What is the real risk of transmission of HEV through blood transfusions?
- What genotypes can cause chronic infection?
- Mechanism of interaction between T-cells and HEV?
References
- ↑ 1.0 1.1 Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J; et al. (2012). "Hepatitis E." Lancet. 379 (9835): 2477–88. doi:10.1016/S0140-6736(11)61849-7. PMID 22549046.
- ↑ 2.0 2.1 Wedemeyer H, Pischke S, Manns MP (2012). "Pathogenesis and treatment of hepatitis e virus infection". Gastroenterology. 142 (6): 1388–1397.e1. doi:10.1053/j.gastro.2012.02.014. PMID 22537448.